Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06514378
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-16
Brief Title:
Safety of Endobronchial Mesenchymal Stromal Cells in the Treatment of Chronic Lung Allograft Dysfunction
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Open Label Randomised Controlled Clinical Trial to Asses the Safety of Endobronchial Administration of Allogneic Mesenchymal Stromal Cells in Patients With Lung Trasplant Chronic Rejection Endosclad Study
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ENDOSCLAD
Brief Summary:
Lung transplantation is the only therapeutic alternative for more and more patients with respiratory diseases in their most advanced stages
The most limiting factor to achieve long term survival si chronic lung allograft dysfunction a multifactorial disease without an effective treatment
The immunomodulatory capacity of mesenchymal stem cells enables them to be a potential therapeutic agent for this condition
The objective of this study is to assess the safety of endobronchial administration of allogeneic MSCs in patients with chroniclung allograft dysfunction
The most limiting factor to achieve long term survival si chronic lung allograft dysfunction a multifactorial disease without an effective treatment
The immunomodulatory capacity of mesenchymal stem cells enables them to be a potential therapeutic agent for this condition
The objective of this study is to assess the safety of endobronchial administration of allogeneic MSCs in patients with chroniclung allograft dysfunction
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None